Campbell Newman Asset Management Inc. Sells 21,646 Shares of Johnson & Johnson $JNJ

Campbell Newman Asset Management Inc. decreased its stake in Johnson & Johnson (NYSE:JNJ) by 95.8% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 955 shares of the company’s stock after selling 21,646 shares during the period. Campbell Newman Asset Management Inc.’s holdings in Johnson & Johnson were worth $233,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. increased its position in Johnson & Johnson by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 240,349,660 shares of the company’s stock valued at $49,740,362,000 after purchasing an additional 3,731,074 shares during the period. State Street Corp lifted its holdings in Johnson & Johnson by 1.3% in the fourth quarter. State Street Corp now owns 133,869,843 shares of the company’s stock valued at $27,704,364,000 after buying an additional 1,663,782 shares during the period. Auto Owners Insurance Co boosted its position in shares of Johnson & Johnson by 22,225.6% during the 4th quarter. Auto Owners Insurance Co now owns 69,419,308 shares of the company’s stock valued at $1,436,633,000 after purchasing an additional 69,108,368 shares in the last quarter. Geode Capital Management LLC grew its position in shares of Johnson & Johnson by 3.1% during the 4th quarter. Geode Capital Management LLC now owns 57,953,747 shares of the company’s stock worth $11,967,947,000 after buying an additional 1,738,292 shares during the period. Finally, Norges Bank acquired a new stake in Johnson & Johnson in the fourth quarter worth $6,924,523,000. 69.55% of the stock is currently owned by institutional investors.

Insider Transactions at Johnson & Johnson

In related news, EVP Kathryn E. Wengel sold 10,000 shares of the firm’s stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the completion of the sale, the executive vice president owned 114,288 shares in the company, valued at approximately $27,560,551.20. This trade represents a 8.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson reported encouraging mid-June clinical and product updates, including strong TALVEY combination data in relapsed/refractory multiple myeloma, positive Phase 2/3 ENERGY results for IMAAVY in warm autoimmune hemolytic anemia, and wider U.S. availability of its TECNIS PureSee lens. These developments support the company’s growth narrative in oncology, rare disease and medtech. Article: How Oncology, Rare Disease and MedTech Wins At Johnson & Johnson (JNJ) Has Changed Its Investment Story
• Positive Sentiment: The company is investing more than $1 billion to expand its Jacksonville, Florida vision manufacturing, packaging and distribution footprint, part of a broader $55 billion U.S. manufacturing and R&D push. Investors may view the expansion as a sign of long-term confidence in demand and domestic supply-chain strength. Article: Johnson & Johnson (JNJ) Is Spending More Than $1 Billion On Jacksonville Vision Expansion
• Neutral Sentiment: Additional coverage highlighted the same U.S. manufacturing investment strategy and suggested it could strengthen Johnson & Johnson’s Vision business, but the article did not add materially new financial details beyond the announced expansion. Article: How Johnson & Johnson (JNJ) Is Using U.S. Manufacturing Investment to Strengthen Its Vision Business
• Neutral Sentiment: Several third-party opinion pieces reiterated Johnson & Johnson as a defensive, high-quality healthcare holding, which may support investor sentiment but did not introduce new company-specific catalysts. Article: How Johnson & Johnson (JNJ) Is Using U.S. Manufacturing Investment to Strengthen Its Vision Business
• Neutral Sentiment: Analyst-style commentary also framed J&J as an attractive portfolio stock, but this was largely a valuation/quality argument rather than a fresh operational driver. Article: Johnson & Johnson: An Excellent Portfolio Option To Barbell AI, Initiate Buy Rating

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Daiwa Securities Group raised their price objective on Johnson & Johnson from $237.00 to $246.00 and gave the company an “outperform” rating in a research note on Thursday, April 16th. Morgan Stanley set a $283.00 price objective on shares of Johnson & Johnson in a report on Wednesday, April 15th. TD Cowen started coverage on shares of Johnson & Johnson in a research report on Wednesday, April 8th. They set a “buy” rating and a $250.00 target price for the company. HSBC raised their price target on shares of Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Finally, Weiss Ratings downgraded Johnson & Johnson from a “buy (b)” rating to a “buy (b-)” rating in a research note on Monday, June 15th. Twenty research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $253.04.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $239.66 on Wednesday. The stock has a 50 day moving average of $230.44 and a 200 day moving average of $228.67. The company has a market capitalization of $576.91 billion, a price-to-earnings ratio of 27.71, a PEG ratio of 2.27 and a beta of 0.26. Johnson & Johnson has a 12 month low of $150.73 and a 12 month high of $251.71. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. During the same quarter in the prior year, the company earned $2.77 EPS. The business’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. As a group, sell-side analysts forecast that Johnson & Johnson will post 11.57 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were given a dividend of $1.34 per share. The ex-dividend date was Tuesday, May 26th. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a yield of 2.2%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 61.97%.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.